Works matching IS 11781653 AND DT 2015 AND VI 8 AND IP 5


Results: 8
    1
    2
    3
    4
    5

    Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

    Published in:
    Patient, 2015, v. 8, n. 5, p. 445, doi. 10.1007/s40271-015-0137-9
    By:
    • Gathe, Joseph;
    • Arribas, Jose;
    • Lunzen, Jan;
    • Garner, Will;
    • Speck, Rebecca;
    • Bender, Randall;
    • Shreay, Sanatan;
    • Nguyen, Thai
    Publication type:
    Article
    6
    7
    8